Indolent Lymphoma Market

Market Overview:

The 7 major indolent lymphoma markets are expected to exhibit a CAGR of 5.92% during 2024-2034.

The indolent lymphoma market has been comprehensively analyzed in IMARC's new report titled "Indolent Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Indolent lymphoma, also referred as low-grade lymphoma, is a type of non-Hodgkin lymphoma (NHL) characterized by its slow-growing nature and low aggressiveness. It arises from abnormal lymphocytes, a variety of white blood cells, primarily in the lymph nodes but can involve other lymphoid tissues as well, such as the spleen, bone marrow, gastrointestinal tract, etc. The most common symptom is painless swelling of lymph nodes in the neck, armpits, groin, etc. Various other potential indications may include fatigue, unexplained weight loss, night sweats, recurrent infections, a general feeling of malaise, etc. The diagnosis of indolent lymphoma typically begins with a comprehensive medical history review and physical examination by a healthcare professional, followed by numerous diagnostic procedures. These investigations may include blood tests to assess overall health, imaging scans like computed tomography (CT) or positron emission tomography (PET) scans to visualize the lymph nodes and other organs, a lymph node biopsy to obtain a tissue sample for microscopic examination by a pathologist, etc. Additionally, flow cytometry and genetic tests may be performed to analyze the characteristics as well as the genetic makeup of the lymphoma cells.

The increasing cases of chromosomal abnormalities, including deletions, amplifications, rearrangements, etc., which can disrupt the normal functioning of genes involved in cell cycle regulation, DNA repair, and apoptosis, are primarily driving the indolent lymphoma market. In addition to this, the widespread adoption of CAR-T cell therapy, since it utilizes genetically modified T cells to eliminate cancer cells and achieve long-term remission while minimizing treatment-related toxicity, is further creating a positive outlook for the market. Moreover, the inflating application of targeted therapies, such as kinase inhibitors and BCL2 inhibitors, that aim to inhibit specific molecules or pathways involved in cancer growth, resulting in more effective and selective treatment, is acting as another significant growth-inducing factor. Apart from this, the ongoing advancements in molecular profiling techniques, including the introduction of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis, which can identify genetic alterations that contribute to disease development and progression, thereby guiding targeted treatment approaches, are expected to drive the indolent lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the indolent lymphoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for indolent lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the indolent lymphoma market in any manner.

Key Highlights:

• Indolent lymphoma is responsible for 41% of all non-Hodgkin lymphoma cases in North America and Northern Europe.
• It primarily affects older persons, with men and women affected nearly equally.
• White people have a greater incidence rate than black and Asian people.
• The risk of acquiring indolent lymphoma rises with age.
• It is uncommon in persons under the age of 40 and extremely rare in children.
• For patients who were previously diagnosed with an AIDS-defining disease, the likelihood of acquiring indolent lymphoma is 14 times higher.

Drugs:

Duvelisib is an oral phosphoinositide 3-kinase (PI3K) inhibitor and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to promote malignant cell growth and survival. PI3K signaling has been associated with malignant cell proliferation and is expected to play a role in the development and continued existence of a supportive tumor microenvironment.

ME-401, a selective PI3Kδ inhibitor, is being investigated as an oral, once-daily treatment for individuals with indolent B-cell malignancies, such as follicular lymphoma. Clinical trials are evaluating ME-401's efficacy and safety as an independent agent and in combination with other modalities. It will be delivered on an intermittent dosing schedule (ID) and in a time-limited way when dosed in combination.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the indolent lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the indolent lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current indolent lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the indolent lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the indolent lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the indolent lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of indolent lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of indolent lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of indolent lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with indolent lymphoma across the seven major markets?
• What is the size of the indolent lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of indolent lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Indolent Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for indolent lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the indolent lymphoma market?
• What are the key regulatory events related to the indolent lymphoma market?
• What is the structure of clinical trial landscape by status related to the indolent lymphoma market?
• What is the structure of clinical trial landscape by phase related to the indolent lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the indolent lymphoma market?